PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPYLPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN
申请人:Kim Soojin
公开号:US20090312331A1
公开(公告)日:2009-12-17
Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well.
Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also provided.
提供了选择性制备新型稳定晶态盐形式的过程,即有选择性和一致性地制备甲磺酸盐的N-1型和盐酸盐的N-1型和N-4型的p38激酶抑制剂4-[[5-[(环丙基氨基)羰基]-2-甲基苯基]氨基]-5-甲基-N-丙基吡咯[2,1-f][1,2,4]三嗪-6-羧酰胺。该过程最好使用包括甲酸/丙酮和甲酸/甲基乙酮的溶剂体系,产生具有适当流动性和所需粒径的晶体,也可以使用N,N-二甲基甲酰胺和N,N-二甲基乙酰胺等溶剂。还提供了上述自由基的N-1型甲磺酸盐和盐酸盐的N-1型和N-4型晶体的新型晶体形式,含有这种新型形式的药物组合物以及治疗p38激酶相关疾病,包括类风湿性关节炎的方法。